leadf
logo-loader
viewChimeric Therapeutics Ltd
(
ASX:CHM
)

Chimeric Therapeutics new very experienced COO has bold vision to move CAR T cell therapy forward

Chimeric Therapeutics (ASX: CHM) newly appointed COO Jennifer Chow joined Steve Darling from Proactive to talk about her vision for the company. Chow talks about her background working in cell therapy and how Chimeric hopes to be a big player in it.

Chow also told Proactive about their lead drug CLTX-CAR T which is currently in Phase 1 clinical trials. That drug look to be a treatment for patients with Glioblastoma and potentially other cancers as well.

Quick facts: Chimeric Therapeutics Ltd

Follow
ASX:CHM

Price: 0.335 AUD

Market Cap: $111.7 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Chimeric Therapeutics with Proactive at the ASX Small and Mid Cap Conference

Chimeric Therapeutics Ltd (ASX:CHM)'s Jennifer Chow speaks to Proactive's Andrew Scott from the ASX Small and Mid Cap Conference - September 2021. Chimeric is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. Its lead...

1 week, 4 days ago

2 min read